Key Drivers
- Liquidity Cushion
- Cash Burn
- Negative Margins
AIAI Summary
NAMS has shifted from a survival story to a catalyst-driven execution story: its $707M cash cushion reduces near-term financing risk, but upside now depends on obicetrapib clearing regulatory approvals and gaining reimbursement fast enough to justify the still-rich valuation before launch delays or slow uptake erode investor patience.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Cash Burn
- •Negative Margins
NAMS has strong liquidity and minimal debt, but its tiny revenue base, deep recurring losses, and persistent cash burn make the investment case weak despite low near-term solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Range reclaim
- •Near resistance
- •Bounce risk
NAMS has rebounded over the last month, reclaimed the $33-$34 area, and is now testing $35.2-$35.4 resistance, but it still needs a clean breakout to confirm the move.
Sharp drop from $35.42 on 2026-05-28 to the
Sentiment & News
Key News Insights:
- •Conference visibility
- •Obicetrapib spotlight
- •Equity hires
NewAmsterdam Pharma is staying highly visible with upcoming scientific and investor conference presentations, including AAIC data on obicetrapib for early Alzheimer's prevention, while also adding staff through inducement share grants.
The updates are modestly positive for sentiment, reinforcing pipeline visibility and corporate activity without changing near-term fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings